Skip to main content
TVTX logo

TVTX · Travere Therapeutics, Inc. · Investor Relations

Track TVTX — free
$48.80 -1.45 (-2.88%) Play latest call Q3 2026 earnings call transcript
Market Cap
$4.82B
Shares
95.99M
Volume · Nov 19 420.93K Avg daily vol (3M) 1.82M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-12 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 Travere Therapeutics to Participate at Upcoming Investor Conferences
2026-11-02 Travere Therapeutics Reports Third Quarter 2026 Financial Results
2026-10-26 Travere Therapeutics to Report Third Quarter 2026 Financial Results
2026-10-23 Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
2026-10-12 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
2026-09-23 Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
2026-09-21 Travere Therapeutics Announces Planned Chief Executive Officer Transition
2026-09-17 Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-11 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-12 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05 Travere Therapeutics to Participate at Upcoming Investor Conferences
2026-08-04 Travere Therapeutics Reports Second Quarter 2026 Financial Results
2026-07-28 Travere Therapeutics to Report Second Quarter 2026 Financial Results
2026-07-10 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-16 Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
2026-06-11 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-04 Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
2026-06-02 Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
2026-05-27 Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
2026-05-12 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 Travere Therapeutics to Participate at Upcoming Investor Conferences
2026-05-07 Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
2026-05-05 Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Past events

Date Event Type
2026-11-17 Jefferies London Healthcare Conference Conference
2026-11-17 Jefferies Global Healthcare Conference Conference
2026-11-16 UBS Global Biopharma Conference Conference
2026-11-11 Stifel 2026 Healthcare Conference Conference
2026-11-10 Guggenheim Global Healthcare Conference Conference
2026-11-10 Guggenheim 3rd Annual Healthcare Innovation Conference Conference
2026-11-02 Travere Therapeutics, Inc. Q3 FY2026 Earnings Call Earnings call
2026-09-24 Stifel 2026 Virtual Immunology and Inflammation Forum Event
2026-09-10 2026 Cantor Global Healthcare Conference Conference
2026-09-09 Citi 2026 Biopharma Back to School Conference Conference
2026-09-08 Wells Fargo 21st Annual Healthcare Conference Conference
2026-08-11 Canaccord Genuity's 46th Annual Growth Conference Conference
2026-08-04 Travere Therapeutics Second Quarter 2026 Earnings Results Earnings call
2026-06-08 Goldman Sachs 47th Annual Global Healthcare Conference 2026 Conference
2026-06-03 2026 Jefferies Global Healthcare Conference Conference
2026-06-02 Business Update Call Event
2026-05-13 BofA Securities 2026 Health Care Conference Conference
2026-05-04 Travere Therapeutics First Quarter 2026 Earnings Results Earnings call
2026-04-13 Travere Therapeutics FDA Approval of FILSPARI in FSGS Conference Call Conference
2026-02-19 Travere Therapeutics Fourth Quarter and Full Year 2025 Earnings Results Earnings call
2026-02-11 Guggenheim Emerging Outlook: Biotech Summit 2026 Event
2026-01-13 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-02 8th Annual Evercore Healthcare Conference Conference
2025-11-18 Jefferies Global Healthcare Conference Conference
2025-11-13 TD Cowen Immunology & Inflammation Summit Event

Source: https://ir.travere.com/overview/default.aspx

Key facts CIK 1438533 CUSIP 89422G107 13F (30d) 353 filings 328 filers Visit website Investor relations